Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Menu Back to Meeting-Details

Call for Posters DIA/FDA Oligonucleotide-Based Therapeutics Conference

6/3/2024 12:00:00 AM - 8/8/2024 11:59:00 PM


Read Submission Guidelines| Submit

Abstract Submission Deadline: Thursday, August 8

Notification: Week of September 3

Final Poster PDF Presentations Due: October 7

Meeting Dates: October 28-30

Location: Washington, DC

Questions: Contact

Poster Abstract Overview and Topics

Get involved! DIA and the Program Committee invite you to submit a poster abstract to be presented during the DIA/FDA Oligonucleotide-Based Therapeutics Conference, October 28-30. Posters describing research, best practices, or approaches related to oligonucleotides in areas of Clinical, Non-Clinical, and CMC will be considered for acceptance.

NonClinical Track

The nonclinical sessions are designed to provide updates and discussion on recent advancements in nonclinical development of oligonucleotide therapeutics. All mechanisms of RNA targeting therapeutics will be represented with a particular interest in delivery to non-hepatic tissues.

Clinical Development Track

These sessions will provide updates on the recent progress made with oligonucleotides in the clinic. Programs in various stages of development will highlight the challenges faced, lessons learned, and offer potential solutions and innovative ideas for clinical development of oligonucleotide therapeutics.

Chemistry, Manufacturing, and Controls (CMC) Track

The CMC track will cover a wide range of current oligonucleotide science and feature expert speakers from industry and regulatory agencies.

Poster Submissions may Include, but are not Limited to, the Following Oligonucleotide-Related Topics:

  • Assay Development and Optimization
  • Clinical Pharmacology, including Oligonucleotide ADME
  • Clinical Safety
  • Formulations
  • Hot Topics in Oligonucleotide Research
  • Impurities
  • Manufacturing
  • Nonclinical Efficacy Models
  • Toxicology, Including Updates in Oligo Toxicology (Clinical and Nonclinical)
  • Novel Mechanisms for Intervention
  • Novel Oligonucleotide Therapeutics
  • Oligonucleotide Conjugation and Tissue Targeting
  • Oligonucleotide Therapeutics (Rare Diseases, Immuno-oncology, Metabolic and Cardiovascular Diseases, Neuromuscular Conditions)
  • Regulatory Affairs, Including Oligonucleotide Regulatory Guidance
  • Targeting and Delivery, Including Target Identification Screening Methods (Discovery)
  • Translational Experience

We ask that all poster abstracts be noncommercial and scientific in nature, and not appear as a marketing opportunity. To submit a poster abstract, please follow the guidelines

Abstract Details and Guidelines

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.